Neonatal seizure

Neurelis Announces Five Poster Presentations for the Annual Meeting of the American Academy Of Neurology

Retrieved on: 
Monday, April 19, 2021

In addition, the data shows that patients reported feeling like their usual self within two hours after VALTOCO administration.

Key Points: 
  • In addition, the data shows that patients reported feeling like their usual self within two hours after VALTOCO administration.
  • To be able to continue on with your day is very meaningful for patients with seizure clusters.
  • In a long-term, open-label, repeat-dose clinical trial, the safety of VALTOCO was evaluated, and more than 4,000 seizures were treated.
  • Serious and fatal adverse reactions, including "gasping syndrome", can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO.

Global Epileptic Seizures Treatment Market to Surpass US$ 4.5 Billion by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Wednesday, January 27, 2021

According to Coherent Market Insights, the global epileptic seizures treatment market is estimated to be valued at US$ 3.0 billion in 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global epileptic seizures treatment market is estimated to be valued at US$ 3.0 billion in 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027).
  • Manufacturers in the epileptic seizures treatment market are continuously focusing on investing in R&D of new drugs to meet demand for effective medications for treating epilepsy, which is expected to drive growth of the epileptic seizures treatment market over the forecast period.
  • The increasing collaborations, partnerships, and agreements between the major players for developing more advanced drugs for epileptic seizures treatment is expected to accelerate the epileptic seizures treatment market growth.
  • The global epileptic seizures treatment market is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027), owing to the increasing product approvals and launches for epileptic seizures treatment.

Persons With Alzheimer's Disease More Likely To Experience Recurring Epileptic Seizures

Retrieved on: 
Monday, July 15, 2019

Also reported at AAIC 2019, persons with dementia are at higher risk of having recurring seizures and of experiencing seizures for the first time at a younger age, compared to people without dementia.

Key Points: 
  • Also reported at AAIC 2019, persons with dementia are at higher risk of having recurring seizures and of experiencing seizures for the first time at a younger age, compared to people without dementia.
  • Alzheimer's disease causes death of neurons, and researchers hypothesize this may contribute to abnormal electrical activity in the brain that leads to epileptic seizures.
  • Seizures can be a symptom of epilepsy, but not all people who experience seizures have epilepsy.
  • And persons with Alzheimer's disease were also twice as likely to have had a previous seizure (3.14% vs. 1.57%).